In addition, antisense nucleic acid technique on CR-1 [28], and antagonist of the CR-1 CFC domain have been reported to inhibit human breast cancer, colon cancer and testicular cancer cells growth [29], suggesting that CR-1 is a valuable therapeutic target for targeting CSLCs in ESCC. Here, CR1 is linked to testicular cancer.